Proxima (formerly VantAI) raised $80 million in seed funding led by DCVC and Nvidia to advance AI-dr...
The AMW Read
The article updates the player map for AI-driven drug discovery with an $80M seed round, though it does not trigger cross.§D as the amount is below the $500M threshold.
NoveltySignificance
Healthcare & Bio · Player Map
Proxima (formerly VantAI) raised $80 million in seed funding led by DCVC and Nvidia to advance AI-driven proximity therapeutics. The startup designs drugs to control protein interactions, specifically targeting undruggable targets via molecular glues. This signifies a systemic shift where AI-native data generation becomes the core differentiator in biotech. By focusing on complex systems, Proxima aims to redefine therapeutic boundaries for oncology and autoimmune diseases. 🧬🤖